UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)*

Generation Bio Co.

(Name of Issuer)

Common stock, par value \$0.0001 per share (Title of Class of Securities)

37148K100

(CUSIP Number)

December 31, 2022 (Date of Event Which Requires Filing of the Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

 \boxtimes Rule 13d-1(c)

□ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO. 37148K100

1.	NAME OF REPORTING PERSON						
	PFM Health Sciences, LP						
2.	CHECK THE APPROPRIATE	BOX IF A I	MEMBER OF A GROUP	(a)			
				(b)	X		
3.	SEC USE ONLY						
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
	NUMBER OF	5.	SOLE VOTING POWER				
	SHARES BENEFICIALLY OWNED BY		SHARED VOTING POWER				
	EACH REPORTING		2,903,192 shares				
	PERSON WITH	7.	SOLE DISPOSITIVE POWER 0				
		8.	SHARED DISPOSITIVE POWER See Row 6 above				
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above						
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	$4.9\%^{1}$						
12.	TYPE OF REPORTING PERSO IA; PN	NC	,				

1 The percentages reported in this Schedule 13G are based upon 59,422,697 shares of common stock outstanding as of October 31, 2022 (according to the issuer's Form 10-Q as filed with the Securities and Exchange Commission on November 3, 2022).

1.	NAME OF REPORTING PERSON						
	PFM Health Sciences GP, LLC						
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP						
		\boxtimes					
3.	SEC USE ONLY						
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
	NUMBER OF	5.	SOLE VOTING POWER				
	SHARES BENEFICIALLY OWNED BY		SHARED VOTING POWER				
	EACH		2,903,192 shares				
	REPORTING PERSON WITH		SOLE DISPOSITIVE POWER				
		8.	SHARED DISPOSITIVE POWER See Row 6 above				
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above						
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	4.9%						
12.	TYPE OF REPORTING PERSON OO						

CUSIP NO. 37148K100

1.	NAME OF REPORTING PERSON						
	Partner Asset Management, LLC						
2.	CHECK THE APPROPRIATE E	BOX IF A M	MEMBER OF A GROUP		_		
				(a)			
				(b)	\boxtimes		
3.	SEC USE ONLY						
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware						
	NUMBER OF	5.	SOLE VOTING POWER				
	SHARES BENEFICIALLY OWNED BY	6.	SHARED VOTING POWER				
	EACH		2,903,192 shares				
	REPORTING PERSON WITH		SOLE DISPOSITIVE POWER				
		8.	SHARED DISPOSITIVE POWER See Row 6 above				
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above						
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	4.9%						
12.	TYPE OF REPORTING PERSON OO						

1.	NAME OF REPORTING PERSON					
	Brian D. Grossman					
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)					
				(b)	\boxtimes	
3.	SEC USE ONLY					
4.	CITIZENSHIP OR PLACE OF ORGANIZATION U.S. Citizen					
NUMBER OF		5.	SOLE VOTING POWER			
	SHARES BENEFICIALLY OWNED BY		SHARED VOTING POWER			
	EACH REPORTING		2,903,192 shares			
PERSON WITH		7.	SOLE DISPOSITIVE POWER 0			
		8.	SHARED DISPOSITIVE POWER See Row 6 above			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON See Row 6 above					
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	4.9%					
12.	TYPE OF REPORTING PERSON IN					

Item 1(a) Name of Issuer Generation Bio Co.

 Item 1(b)
 Address of Issuer's Principal Executive Offices

 301 Binney Street, Cambridge, Massachusetts 02142

Item 2(a) Name of Person Filing

This Schedule 13G is being jointly filed by PFM Health Sciences, LP ("PFM"), PFM Health Sciences GP, LLC ("PFM-GP"), Partner Asset Management, LLC ("PAM"), and Brian D. Grossman ("Grossman" and, collectively with PFM, PFM-GP, and PAM, the "Reporting Persons") with respect to the common stock of the above-named issuer owned by PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("HCM") and PFM Biotech Opportunities LP, a Delaware limited partnership ("BO" and, collectively with HCM, the "Funds").

PFM is the investment advisor for the Funds. PAM is the general partner of HCM. PFM-GP is the general partner of PFM and the manager of PAM. Grossman is the sole member of PFM-GP.

The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

Item 2(b) Address or Principal Business Office or, if none, Residence

The address of the principal business office of each of the Reporting Persons is c/o PFM Health Sciences, LP, 475 Sansome Street, Suite 1720, San Francisco, California 94111.

Item 2(c) Citizenship

PFM is organized as a limited partnership under the laws of the State of Delaware. Each of PFM-GP and PAM is organized as a limited liability company under the laws of the State of Delaware. Grossman is a U.S. citizen.

Item 2(d) Title of Class of Securities

Common stock, par value \$0.0001 per share

Item 2(e) CUSIP Number

37148K100

Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

- (a) \Box Broker or dealer registered under Section 15 of the Exchange Act;
- (b) \Box Bank as defined in Section 3(a)(6) of the Exchange Act;
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act;
- (e) \Box An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) \Box An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) \Box A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
- (k) \Box Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4 Ownership A. PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC PFM, PFM-GP and PAM may be deemed to beneficially own 2,903,192 shares of Common Stock. (a) (b) The number of shares PFM, PFM-GP and PAM may be deemed to beneficially own constitutes approximately 4.9% of the Common Stock outstanding. (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 2,903,192 sole power to dispose or to direct the disposition of: 0 (iii) shared power to dispose or to direct the disposition of: 2,903,192 (iv) B. Brian D. Grossman (a) Grossman may be deemed to beneficially own 2,903,192 shares of Common Stock. The number of shares Grossman may be deemed to beneficially own constitutes approximately 4.9% of the Common (b) Stock outstanding. Number of shares as to which such person has: (c) (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 2,903,192 sole power to dispose or to direct the disposition of: 0 (iii) (iv) shared power to dispose or to direct the disposition of: 2,903,192 Item 5 **Ownership of Five Percent or Less of a Class** If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following \boxtimes . Item 6 **Ownership of More than Five Percent on Behalf of Another Person** Not Applicable Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company See Item 2 above

CUSIP N	O. 37148K100	13G	Page 9 of 10 Pages
Item 8	Identification an Not Applicable	l Classification of Members of the Group	
Item 9	Notice of Dissolu Not Applicable	ion of Group	
Item 10	held for the purpo	I certify that, to the best of my knowledge and belief, the securities re se of or with the effect of changing or influencing the control of the is nection with or as a participant in any transaction having that purpos	ssuer of the securities and were not acquired and

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

By:

Dated this 14th day of February, 2023.

PFM HEALTH SCIENCES, LP

PFM HEALTH SCIENCES GP, LLC

/s/ Darin Sadow

By: PFM Health Sciences GP, LLC, its general partner

By: /s/ Darin Sadow Darin Sadow, Authorized Signatory

PARTNER ASSET MANAGEMENT, LLC

By: PFM Health Sciences GP, LLC, its manager

Darin Sadow, Authorized Signatory

BRIAN D. GROSSMAN

By: /s/ Darin Sadow

Darin Sadow, attorney-in-fact^{*}

By: /s/ Darin Sadow Darin Sadow, Authorized Signatory

^{*} Darin Sadow is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011.